Stephen Feider sold $170k of BBNX
Chief Financial Officer at Beta Bionics, Inc.. 10,000 shares at an average of $17.04, traded Jun 26, 2026, filed Jun 30, 2026.
Score components
- +22RoleCFO
- +11Trade size$170k at market
- 0Share of holdings soldSold 5.8% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002048588-26-000009, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | MOption exercise Common Stock10b5-1 | +4,982 | $5.10 | $25k | 171,035 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stock10b5-1 | -5,104 | $17.05 | $87k | 165,931 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Common Stock10b5-1 | +4,896 | $5.10 | $25k | 170,827 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stock10b5-1 | -4,896 | $17.03 | $83k | 165,931 | Jun 30, 2026 |
| Jun 26, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -4,982 | $0.00 | $0 | 44,713 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -4,896 | $0.00 | $0 | 39,817 | Jun 30, 2026 |
Related signals
Other insiders at Beta Bionics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $7,015 370 shares | -1% | |
| 26Weak | Beta Bionics, Inc. | Christy Jones director | $148k 6,430 shares | -25% | |
| 40Moderate | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $665k 35,994 shares | -29% | |
| 40Moderate | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $620k 30,779 shares | -35% | |
| 17Weak | Beta Bionics, Inc. | Mike Mensinger Chief Product Officer | $58k 2,650 shares | -1% | |
| 10Weak | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $12k 775 shares | -1% | |
| 41Moderate | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $681k 36,870 shares | -30% | |
| 30Weak | Beta Bionics, Inc. | Sean Saint President & CEO | $113k 5,641 shares | -1% | |
| 40Moderate | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $102k 5,327 shares | -4% | |
| 39Weak | Beta Bionics, Inc. | Mike Mensinger Chief Product Officer | $84k 4,375 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.